A recent MedCity News webinar, sponsored by Mercury, convened venture capitalists and health tech leaders to discuss investment strategies and the growing impact of artificial intelligence in early stage healthcare startups. Panelists shared insights on how artificial intelligence is transforming drug target identification and streamlining time-consuming tasks, significantly influencing corporate valuation and development strategies in the sector.
Gurdane Bhutani, managing partner of MBX Capital, described his firm’s approach to investing across three primary verticals: targeting upstream drivers of health outcomes, supporting health tech companies that use artificial intelligence to improve care quality, and backing innovations in biotech research tools, diagnostics, and therapeutics. Morgan Cheatham, partner and head of healthcare and life sciences at Breyer Capital, emphasized the twin investment pillars of artificial intelligence and precision medicine—highlighting their focus on startups at the intersection of health, technology, and life sciences. Ben Kromnick, with a background in big data and machine learning for major healthcare and insurance companies, currently leads Mercury’s healthcare and life sciences business, leveraging large clinical datasets to advance research and development.
The panel delved into the specialized applications of artificial intelligence in biotechnology and healthcare, moving beyond broad platform solutions to examine targeted use cases. Cheatham illustrated how companies focusing on autoimmune therapies might develop custom artificial intelligence models specifically to reduce immunogenicity risks, thereby increasing the probability of clinical and commercial success. He also stressed the importance of in vivo validation data as a driver for external business partnerships and as a catalyst for securing subsequent rounds of funding. Other key discussion points included best practices for grant funding, approaches to capital valuation, lean startup strategies, the use of artificial intelligence for risk mitigation, and the unique role of family offices in early stage funding. The session provided practical tips for healthcare entrepreneurs navigating the funding landscape and showcased the integral role of artificial intelligence in shaping the next generation of medical innovation.
